Find News

Filter articles

Applied Filters

Showing 71 to 80 of 888 results

Allergan pays $750m to resolve antitrust litigation

US29-10-2019Sarah Morgan

Allergan has reached a $750 million deal to resolve antitrust litigation brought against its subsidiary Forest Laboratories over Alzheimer’s drug Namenda.

Novartis takes aim at Indian drug companies over Entresto generics

India, US29-10-2019Rory O'Neill

Swiss pharmaceutical company Novartis has filed a patent infringement lawsuit against three Indian rivals in a US federal court over proposed generics of its heart failure drug Entresto.

Philippines: fake drugs make up 25% of counterfeits

Philippines28-10-2019Saman Javed

The National Committee on IP Rights of the Philippines prevented more than PHP455 million worth of counterfeit medicines and personal care products from reaching consumers in the first seven months of this year.

US committee votes in favour of Pelosi’s drug pricing plan

US21-10-2019Saman Javed

The US House Committee on Energy & Commerce has voted to advance a drug pricing plan which would lower the cost of many prescription drugs.

Fed Circuit rules against Actavis knee pain generic

US11-10-2019Saman Javed

Actavis Laboratories cannot market a generic version of Horizon Pharma’s knee pain treatment, an appeals court has ruled.

J&J invests $500m into global HIV and TB treatment

US10-10-2019Saman Javed

Johnson & Johnson has committed $500 million to research and development programmes over the next four years in a bid to eliminate HIV and tuberculosis across the world by 2030.

California outlaws pay-for-delay deals

US09-10-2019Sarah Morgan

California has become the first US state to ban pay-for-delay deals in the pharmaceutical industry.

Sandoz secures victory against GSK in passing off case

UK08-10-2019Sarah Morgan

The English High Court has sided with pharmaceutical company Vectura and Novartis-owned Sandoz in a passing off lawsuit brought by rival GSK.

Fed Circuit overturns Apotex’s PTAB victory

US07-10-2019Sarah Morgan

The US Court of Appeals for the Federal Circuit last week reversed a Patent Trial and Appeal Board decision, which found that claims in an OSI Pharmaceuticals patent for cancer treatment were obvious.

Bausch targets Sandoz over IBS generic

US03-10-2019Rory O'Neill

Canadian pharmaceutical company Bausch Health is suing Sandoz for patent infringement over its notice of intent to release a generic version of Xifaxan, Bausch’s irritable bowel syndrome drug.

Showing 71 to 80 of 888 results